key: cord-0851944-vrk8vt7u
authors: Alghamdi, Jahad; Alaamery, Manal; Barhoumi, Tlili; Rashid, Mamoon; Alajmi, Hala; Aljasser, Nasser; Alhendi, Yaseen; Alkhalaf, Hend; Alqahtani, Hanadi; Algablan, Omer; Alshaya, Abdulraham I.; Tashkandi, Nabiha; Massadeh, Salam; Almuzzaini, Bader; Ehaideb, Salleh N.; Bosaeed, Mohammad; Ayoub, Kamal; Yezli, Saber; Khan, Anas; Alaskar, Ahmed; Bouchama, Abderrezak
title: Interferon-induced transmembrane protein-3 genetic variant rs12252 is associated with COVID-19 mortality
date: 2021-04-07
journal: Genomics
DOI: 10.1016/j.ygeno.2021.04.002
sha: 7a466cb512e96e431fde816aa07986f979ebfe10
doc_id: 851944
cord_uid: vrk8vt7u

Interferon-induced membrane proteins (IFITM) 3 gene variants are known risk factor for severe viral diseases. We examined whether IFITM3 variant may underlie the heterogeneous clinical outcomes of SARS-CoV-2 infection-induced COVID-19 in large Arab population . We genotyped 880 Saudi patients; 93.8% were PCR-confirmed SARS-CoV-2 infection, encompassing most COVID-19 phenotypes. Mortality at 90 days was 9.1%. IFITM3-SNP, rs12252-G allele was associated with hospital admission (OR = 1.65 [95% CI; 1.01–2.70], P = 0.04]) and mortality (OR = 2.2 [95% CI; 1.16–4.20], P = 0.01). Patients less than 60 years old had a lower survival probability if they harbor this allele (log-rank test P = 0.002). Plasma levels of IFNγ were significantly lower in a subset of patients with AG/GG genotypes than patients with AA genotype (P = 0.00016). Early identification of these individuals at higher risk of death may inform precision public health response.

Coronavirus disease 2019 (COVID-19) is a viral respiratory illness due to a novel pathogen Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2), that emerged in China and spread worldwide [1, 2] . To date, SARS-CoV-2 infected more than 115 million people, resulting in death reaching 2.5 million, in addition to the societal and economic burden [3] .

Epidemiological data revealed that the majority of COVID-19 infections were asymptomatic or displayed a mild illness, while a sizable number (up to 20%) develop either severe hypoxemic pneumonia or critical illness culminating in death [2, 4, 5] . The large variability in clinical expression and outcomes of COVID-19 was associated with host factors such as old age, gender, comorbidities, ethnicity, and lower economic status [2, 4, 6] . Emerging studies J o u r n a l P r e -p r o o f Journal Pre-proof suggest that host-genetic factors may also contribute to the difference in COVID-19 phenotypes [7] [8] [9] [10] [11] [12] [13] [14] [15] .

Studies investigating the role of host genetic factors in COVID-19 pathogenesis are rapidly growing, revealing several gene susceptibility variants, although with different levels of evidence [7, 8, [10] [11] [12] [13] [14] [15] . Two approaches have been used, including candidate gene [7, 8, 10, 11] or genome-wide association [13, 15] . Selected gene candidates included ACE-2, TMPRSS2, IFITM3, Toll-like receptor 3 (TLR3), and interferon regulatory factor 7 (IRF7) based on their role in SARS-CoV-2 tropism to the human cells, including binding, entry, and replication as well as host-immune response to the virus [7] [8] [9] [10] [11] [12] . Several variants of ACE2 and TMPRSS2 genes were identified, but none was associated with COVID-19 severity [7, 8, 10] . In contrast, the variant G allele rs12252 of IFITM3 gene was recognized as a risk factor for COVID-19 hospital (but not ICU) admission in the Caucasian population, and for severity in Chinese patients [11, 12] . However, both studies included small cohorts that do not reflect the extreme clinical heterogeneity of COVID-19, which ranges from no symptoms to death [11, 12] .

More recently, a large cohort of 659 patients, including life-threatening COVID-19 pneumonia, showed that a small number of patients (3.5%) had variants in TL3 and IRF7 genes associated with the severity of COVID-19 [9] . This strengthened the current understanding of the central role of type I and III interferon (IFN) response in the human defense against SARS-CoV-2 infection. Likewise, genome-wide-association studies identified three gene variants (DPP9, IFNAR2, and OAS1 to 3) associated with host immunity, and ABO blood group , lending further evidence that host immune genetic factors interaction with SARS-CoV-2 may underlie the different clinical outcomes of COVID-19 [13] [14] [15] .

J o u r n a l P r e -p r o o f Journal Pre-proof Therefore, we postulated that the difference in clinical manifestations in COVID-19 might be due to gene variants that govern the host defense mechanisms against the virus [16] . The family of interferon-induced membrane proteins (IFITM 1 to 5) is a critical barrier to the virus entry into the cells. It can block the fusion pore formation between the virus and host membranes, preventing the virus from crossing the cellular membrane. Among the IFITM members, variants of the IFITM3 gene, particularly the G allele rs12252 single nucleotide variant (SNV) has been consistently associated with severe viral diseases, including more recently COVID-19 [11, 12, [17] [18] [19] [20] . Accordingly, we tested the hypothesis that the G allele rs12252 variant might contribute to the severity of COVID-19 in a large cohort of uniquely homogenous ethnic Arab Saudi population infected with SARS-CoV-2 and encompassing all COVID-19 phenotypes. This is with the perspective that a better understanding of the host genetic factors at play in COVID-19 may be crucial to inform preventive and therapeutic interventions.

This is an observational prospective cohort study approved by the Institutional Review Board 

We selected the variant rs12252 in IFITM3 based on previous evidence of its association with other viral respiratory infections, including coronavirus [11, 12, [17] [18] [19] [20] . Likewise, we ensured that its global minimum allele frequency (MAF) was above 5% in the Saudi population.

Genomic DNA was extracted from the peripheral blood using the Puregene Blood Kit (QIAGEN, Germany) following the manufacturer's protocol, the detailed method of the genotyping experiment is provided in the supplementary methods.

patients' demographic, pre-existing comorbidities, signs and symptoms, laboratory results, treatment, complications, and outcome. These complications included acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), shock state, and the need for invasive mechanical ventilation. Time to event was calculated for any cause mortality from the first positive PCR test or diagnostic in PCR negative patients until an event (i.e. hospitalization, Intensive Care Unit (ICU) admission, or death). For patients recruited from quarantine sites, we relied on the patients self-reporting medical history and disease severity, and we followed-up with the patients until complete recovery. Overall, patients were categorized into one of the four groups based on the disease severity; asymptomatic, which include patients without any COVID-19-related symptoms; mild consisted of patients with mild signs and symptoms who did not require hospital admission; severe and critical, comprised patients who were admitted to the hospital ward and ICU, respectively.

We summarized categorical variables as number (%) and continuous variables (numerical variables) as mean and standard deviation (SD) or median and inter-quartile range (IQR). The normality assumptions were assessed for all numerical variables using the Shapiro-Wilk test and graphical representation (i.e., histograms and Q-Q plots). Normally distributed continuous variables were compared using a two-sample independent t-test, otherwise with the Mann-Whitney U test. We compared categorical variables using the Chi-square or Fisher exact test. Allelic frequency of the selected variant was carried out in PLINK to calculate the minor MAF and Hardy-Weinberg Equilibrium [21] . Univariate and multivariate logistic regression were used to assess the association between the selected genetics variant and phenotypes after adjusting for age. Survival distributions of the patients' group were compared using a nonparametric log-rank test. We assessed model fit using the Hosmer-Lemeshow goodness-of-fit test. The odds ratios (OR) were reported for the associations. Log-J o u r n a l P r e -p r o o f Journal Pre-proof rank test was also used to compare survival distribution of patients during hospital stay among disease severities and between different genotypes. We considered a P value of <0.05 statistically significant and used R version 4.0.2 for all statistical analyses.

A total of 952 Saudi patients were enrolled from a tertiary care hospital and two quarantine sites; 72 subjects were excluded because of missing clinical information or low sample quality (Fig. S1 ). Of the remaining 880 patients included in the study, 466 (53%) were monitored as outpatients, and 414 (47%) were treated as inpatients. The main cause of hospital admission was due to COVID-19 in 328 (79.2%) patients, and the remainder 86 (20.8%) were unrelated. However, this latter group was diagnosed with COVID-19 during their hospital stay. Overall, 825 (93.8%) of the patients had a laboratory-confirmed SARS-CoV-2 infection. Table 1 displays the demographic and baseline clinical characteristics of the study population.

Older patients were highly represented in critical and severe groups than mild or asymptomatic groups. The prevalence of major coexisting illnesses and chronic medications such as antihypertensive and antidiabetic therapies were significantly higher in the severe and critical groups. The most-reported signs and symptoms of COVID-19 were fever (61%), dry cough (45%), and shortness of breath (39%) (Table S1) .

Complications. Multiple organs failure, including ARDS, AKI, and shock state, were the most common causes for admission to ICU ( Table 2) (Table S2) . One patient in each group of severe and critical tested positive for seasonal coronavirus and rhinovirus, respectively. As expected, the frequency of nosocomial infection was significantly higher in critical as compared with severe patients.

Therapy. The patients received various medications, including antiviral, antibiotic, anticoagulants, and antithrombotic dictated by their condition during the course of hospitalization (Table S3 ). The patients admitted to ICU were more likely to receive dexamethasone and other steroids than severe patients.

Outcome. Eighty (9.1%) of the 880 patients did not survive COVID-19 at 90 days ( Table 2) .

Non-survivors were significantly older, with multiple previous comorbidities and chronic medications (Table S4) . Likewise, higher mortality was observed among overweight and obese patients (12.3% and 11.1%, respectively). The cause of death was predominantly due to ARDS (55%), followed by cardiopulmonary arrest (50%) and multiple organs failure (32.5%; Table S5 ).

The allelic frequency of rs12252 (IFITM3) and its association with hospital admission as a proxy for disease severity and mortality is provided in showed that non-survivors with AG genotype tend to be younger and healthier, with few comorbidities and progress to severe forms earlier than the groups of patients with AA genotype, although none was statistically significant (Table S6 ).

Kaplan-Meier survival analysis revealed that survival probability is significantly lower in patients carrying the IFITM3-SNP, rs12252 genotype AG/GG (P = 0.01, log-rank test) (Fig.   1A ). Stratifying the analysis by age groups revealed that patients younger than 60 years old and G allele has significantly lower survival probability (Fig. 1B) , but not in the older age groups.

To assess whether the IFITM3-SNP, rs12252 affects the host immune response, we measured the production of IFNγ and TNFα in-vivo in the three genotypes GG, A/G, and A/A matched for age, gender, and COVID-19 severity in 20 patients. The analysis revealed that patients with GG or AG genotype displayed significantly lower plasma levels of IFNγ as compared to the AA genotype (0.65, 0.66, and 1.12 pg/ml, respectively; P = 0.004 and 0.0001 for GG vs.

AA, and AG vs. AA, respectively; Fig. 1 ). No statistical differences in IFNγ levels between AG and GG genotypes were demonstrated, suggesting that a dominance pattern of the association. Plasma levels of TNFα were not associated with the IFITM3-SNP, rs12252

genotype.

Our study shows that the IFITM3-SNP, rs12252, is associated with COVID-19 severity and mortality following SARS-CoV-2 infection in Saudi individuals less than 60 years old. To the best of our knowledge, this is the first genetic study that reveals a gene variant that may increase the odds of death in young individuals infected with SARS-CoV-2. Recent reports of small cohorts of Caucasian and Chinese individuals documented an association between IFITM3-SNP, rs12252, and risk of hospitalization and severity of COVID-19, respectively [11, 12] . Taken together, the findings suggest a prominent role of IFITM3 in the pathogenesis of COVID-19. [17] [18] [19] [20] 22, 23] . The protective mechanisms are not fully elucidated, but findings from IFITM3 Knockout (KO) cells suggest that IFITM3 proteins prevent the viral genomes from entering the cytosol and starting the replication [16] . This was postulated to be through lessening the virus-endosome fusion and accelerating the shuttle of endosomal viral cargo to lysosomes for destruction [24] . On the other hand, a variant, IFITM3-SNP, rs12252 with GG genotype was associated with severity and outcome of several viral illnesses, including influenza A H1N1/09 and H7N9, Hantan virus infection and acute human immunodeficiency (HIV) infection [22, 23, 25, 26] .

In the present study, we show that allele G presence nearly doubles the odds of dying from COVID-19 during SARS-CoV-2 infection. The predictive value of G allele was independent of robust clinical risk factors, such as old age, gender, BMI, or even major underlying comorbidities. Notably, the IFITM3-SNP, rs12252 with A/G genotype enhances significantly the odds of dying for younger population infected with SARS-CoV-2, hence raising a novel hypothesis on the pathogenic mechanisms that may lead to death in this category of the population.

The study also revealed that the frequency of the minor rs12252-G allele was 9%, in Saudis, which is closer to the frequency in the European population (4%), but much lower than East Asia (53%) and global population (24%) as reported in the 1000 genome project [27] . The low frequency of the G-allele in the Saudi population explains why the homozygote genotype was hardly represented in our cohort. Further, the association of rs12252-G allele with clinical expression and outcome of many viral illnesses differed between ethnic groups ranging from none in the European to severity and lethality in the East Asian population [11, 18, 23, 28] . Here, we showed that in a relatively large and homogenous cohort of ethnic J o u r n a l P r e -p r o o f Arabs, the IFITM3, rs12252 with A/G genotype is significantly associated with mortality in COVID-19. The explanation for this discrepancy in outcome between ethnic groups remains unclear but warrants further research as the findings may inform a precision public health response such as social distancing and vaccination.

The mechanisms that underlie the pathogenicity of the IFITM3, rs12252 with minor G allele association with morbidity and mortality are not fully elucidated. The polymorphism was postulated to result in low IFITM3 protein expression [29] , a weakened antiviral activity due to the encoded 21-amino acid truncation [30] , or alteration of cellular localization of the protein between the membrane and endosome [30, 31] . Nevertheless, in KO mouse model lacking IFITM3 challenged with a low dose of influenza virus or diminished viral pathogenicity demonstrated that it results in higher, lung, heart, spleen, and systemic viral replication than the wild-type control [32, 33] . As a consequence, the KO mice developed fulminant pneumonia, arrhythmias, and myocardial damage that rapidly progressed to death.

Lung pathology disclosed edema, hemorrhage, and inflammation, while the heart exhibited myocarditis and enhanced fibrotic response. IL-6 concentration was increased in both lung and heart tissues, thus suggesting that lack of IFMT3 resulted in viral and inflammatoryinduced organ injury and damage [33] .

Lung and heart are common targets of SARS-CoV-2 induced COVID-19, as documented in our cohort. We did not observe any significant difference in the incidence or severity of ARDS, need for mechanical ventilation, hemodynamic instability, or troponin levels between the patients with IFITM3 rs12252-A/A and rs12252-A/G genotypes. However, the patients with the IFITM3 rs12252-A/G genotype were younger, with few comorbidities, had a shorter time from disease onset to admission to ICU, and higher mortality, although these did not reach statistical significance. Likewise, we observed lower circulating IFNγ and higher TNFα in a subset of patients with G allele IFITM3 relative to A/A genotype, indicating a J o u r n a l P r e -p r o o f dysregulated innate immune response of the host carrying the IFITM3 variant. However, this evidence remains indirect, and accordingly, further studies are needed to unravel the precise pathogenic mechanisms at play in individuals with G allele IFITM3 variant.

Our study has some important limitations; first, we prioritized genotyping rs12252 based on its previous role in respiratory viral infections and the a priori probability that it might underlie the clinical outcomes of COVID-19. Another studied variant, rs34481144, has also been reported to be associated with viral respiratory diseases [29] , and the frequency of the combined haplotype involving the two variants has been shown to be in line with standardized mortality ratios [34] . Nevertheless, both variants were reported to be located within the same linkage disequilibrium (LD) block, with strong LD with a mutual variant (rs642194) [35] . Second, we missed recording some early signs and symptoms of admitted patients due to the difficulty to directly communicate with the patients, particularly those admitted immediately with severe forms of the disease, and thus relied solely on the documented information in their electronic health records. Nonetheless, this study benefits from a relatively large sample size of a homogenous population from the same ethnic background, with a very explicit patient phenotyping encompassing a wide range of COVID-19 manifestations. Moreover, we have measured the plasma levels of two biomarkers, although in small subsets that might serve as endophenotypes. If the findings are confirmed on a larger scale, this would further strengthen the observed association at the phenotype level.

In conclusion, this study in the Saudi population showed that the G allele of rs12252 within 

The authors declare that they have no competing interests J o u r n a l P r e -p r o o f 

A Novel Coronavirus from Patients with Pneumonia in China

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

COVID-19 Map -Johns Hopkins Coronavirus Resource Center

Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Viral and host factors related to the clinical outcome of COVID-19

Gender Differences in Patients With COVID-19: Focus on Severity and Mortality

ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population

Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

ACE2, TMPRSS2, and Furin variants and SARS-CoV-2 infection in

Interferon-Induced Transmembrane Protein 3 Genetic Variant rs12252-C Associated with Disease Severity in Coronavirus Disease

The Interferon-induced transmembrane protein 3 gene (IFITM3) rs12252 C variant is associated with COVID-19

Severe Covid-19 GWAS Group, Genomewide Association Study of Severe Covid-19 with Respiratory Failure

Trans-ethnic analysis reveals genetic and non-genetic associations with COVID-19 susceptibility and severity

Genetic mechanisms of critical illness in Covid-19

IFITM-family proteins: The cell's first J o u r n a l P r e -p r o o f line of antiviral defense

The IFITM Proteins Mediate Cellular Resistance to Influenza A H1N1 Virus, West Nile Virus, and Dengue Virus

IFITM3 restricts the morbidity and mortality associated with influenza

Distinct patterns of IFITMmediated restriction of filoviruses, SARS coronavirus, and influenza A virus

IFITM3 rs12252-C variant increases potential risk for severe influenza virus infection in Chinese population

PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses

Interferon-induced transmembrane protein-3 rs12252-C is associated with rapid progression of acute HIV-1 infection in Chinese MSM cohort

Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals

IFITM3 directly engages and shuttles incoming virus particles to lysosomes

Interferon-induced transmembrane protein 3 inhibits Hantaan virus infection, and its single nucleotide polymorphism rs12252 influences the severity of hemorrhagic fever with renal syndrome

Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection

A global reference for human genetic variation

Evaluation of IFITM3 rs12252 Association with Severe Pediatric Influenza Infection

SNP-mediated disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe influenza in humans

The N-Terminal Region of IFITM3 Modulates Its Antiviral Activity by Regulating IFITM3 Cellular Localization

Phosphorylation of the Antiviral Protein Interferon-inducible Transmembrane Protein 3 (IFITM3) Dually Regulates Its Endocytosis and Ubiquitination

Ifitm3 Limits the Severity of Acute Influenza in Mice

IFITM3 protects the heart during influenza virus infection

The frequency of combined IFITM3 haplotype involving the reference alleles of both rs12252 and rs34481144 is in line with COVID-19 standardized mortality ratio of ethnic groups in England

Population genetics of IFITM3 in Portugal and Central Africa reveals a potential modifier of influenza severity